Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HSCSNASDAQ:NXGLNASDAQ:PETVNASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSCSHeart Test Laboratories$3.63-0.5%$3.34$2.36▼$7.57$3.92M2.61121,082 shs3,307 shsNXGLNEXGEL$2.20-0.5%$2.61$1.84▼$5.10$17.06M0.6568,009 shs12,848 shsPETVPetVivo$0.77-4.1%$0.63$0.29▼$0.98$18.57M0.7820,937 shs67,323 shsXAIRBeyond Air$0.19-2.6%$0.22$0.16▼$1.49$15.98M0.251.22 million shs468,488 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSCSHeart Test Laboratories+0.27%-4.70%+4.02%+2.53%-46.26%NXGLNEXGEL+4.25%-1.78%-12.30%-28.71%+4.74%PETVPetVivo0.00%+5.13%+37.74%+47.94%+28.75%XAIRBeyond Air0.00%+0.80%-5.75%-29.58%-84.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHSCSHeart Test Laboratories2.4789 of 5 stars3.53.00.00.02.60.01.3NXGLNEXGEL1.4249 of 5 stars0.05.00.00.02.72.50.0PETVPetVivoN/AN/AN/AN/AN/AN/AN/AN/AXAIRBeyond Air4.4337 of 5 stars3.53.00.03.53.32.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSCSHeart Test Laboratories 3.00Buy$13.00258.13% UpsideNXGLNEXGEL 0.00N/AN/AN/APETVPetVivo 0.00N/AN/AN/AXAIRBeyond Air 3.00Buy$1.50710.81% UpsideCurrent Analyst Ratings BreakdownLatest HSCS, PETV, NXGL, and XAIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2025HSCSHeart Test LaboratoriesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSCSHeart Test Laboratories$14.70K266.94N/AN/A$11.16 per share0.33NXGLNEXGEL$10.23M1.65N/AN/A$0.90 per share2.44PETVPetVivo$1.05M17.75N/AN/A($0.03) per share-25.54XAIRBeyond Air$3.02M5.29N/AN/A$0.27 per share0.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSCSHeart Test Laboratories-$6.61M-$7.48N/AN/AN/AN/A-117.76%-84.09%8/4/2025 (Estimated)NXGLNEXGEL-$3.16M-$0.45N/A∞N/A-52.60%-71.19%-34.79%N/APETVPetVivo-$10.95M-$0.45N/A∞N/A-902.82%-4,813.07%-281.78%6/26/2025 (Estimated)XAIRBeyond Air-$60.24M-$1.06N/AN/AN/A-1,730.00%-226.01%-109.75%6/23/2025 (Estimated)Latest HSCS, PETV, NXGL, and XAIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/23/2025Q4 2025XAIRBeyond Air-$0.14N/AN/AN/A$1.39 millionN/A5/13/2025Q1 2025NXGLNEXGEL-$0.10-$0.09+$0.01-$0.09$2.73 million$2.81 million3/24/2025Q4 2024NXGLNEXGEL-$0.10-$0.08+$0.02-$0.11$2.99 million$3.04 million3/13/2025Q3 2025HSCSHeart Test Laboratories-$2.53-$2.5722-$0.0422-$2.57N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSCSHeart Test LaboratoriesN/AN/AN/AN/AN/ANXGLNEXGELN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSCSHeart Test Laboratories0.011.721.52NXGLNEXGEL0.191.510.93PETVPetVivo0.020.420.47XAIRBeyond AirN/A3.563.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSCSHeart Test Laboratories17.24%NXGLNEXGEL2.21%PETVPetVivo24.55%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipHSCSHeart Test Laboratories1.80%NXGLNEXGEL20.55%PETVPetVivo10.84%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHSCSHeart Test Laboratories101.08 million962,000Not OptionableNXGLNEXGEL107.66 million5.10 millionNot OptionablePETVPetVivo2024.23 million19.06 millionNot OptionableXAIRBeyond Air7086.37 million54.97 millionOptionableHSCS, PETV, NXGL, and XAIR HeadlinesRecent News About These CompaniesBeyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and WebcastMay 20, 2025 | globenewswire.comBeyond Air granted U.S. patent for gaseous nitric oxide deliveryApril 25, 2025 | markets.businessinsider.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Gets Patent for Lung Infection TreatmentApril 25, 2025 | marketwatch.comBeyond Air granted U.S. patent for treatment of NTM infections using gaseous Nitric OxideApril 25, 2025 | msn.comBeyond Air, Inc. Secures U.S. Patent for Novel Nitric Oxide Delivery Method in Treating NTM Lung InfectionsApril 24, 2025 | quiverquant.comBeyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to AutismApril 23, 2025 | finanznachrichten.deNeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to AutismApril 21, 2025 | globenewswire.comNeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory BoardApril 15, 2025 | globenewswire.comBeyond Air subsidiary granted orphan designation for Phelan-McDermid treatmentApril 15, 2025 | markets.businessinsider.comJonesTrading Sticks to Their Buy Rating for Beyond Air (XAIR)April 15, 2025 | markets.businessinsider.comBeyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at HomeApril 9, 2025 | globenewswire.comBeyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at HomeApril 9, 2025 | globenewswire.comBeyond Air subsidiary NeuroNOS announces publication of researchApril 2, 2025 | markets.businessinsider.comBeyond Air announces VUMC as first luminary siteApril 1, 2025 | markets.businessinsider.comBeyond Air Announces Vanderbilt University Medical Center as First Luminary SiteMarch 31, 2025 | globenewswire.comNeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism TherapyMarch 24, 2025 | globenewswire.comBeyond Air (XAIR): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | insidermonkey.comBeyond Air (XAIR): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSCS, PETV, NXGL, and XAIR Company DescriptionsHeart Test Laboratories NASDAQ:HSCS$3.63 -0.02 (-0.55%) As of 12:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.NEXGEL NASDAQ:NXGL$2.20 -0.01 (-0.63%) As of 12:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.PetVivo NASDAQ:PETV$0.77 -0.03 (-4.11%) As of 11:29 AM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.Beyond Air NASDAQ:XAIR$0.18 -0.01 (-2.63%) As of 12:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
